{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:19:38Z","timestamp":1761823178801,"version":"3.37.0"},"reference-count":33,"publisher":"American Association for Cancer Research (AACR)","issue":"4","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background: Men with elevated prostate-specific antigen (PSA) and negative prostate biopsies are at risk for prostate cancer. The antiandrogen bicalutamide has a prolonged half-life, thus potentially allowing an intermittent administration to retain activity while reducing toxicity. We conducted a phase I-II trial of weekly bicalutamide in men with PSA &amp;gt;4 ng\/mL and negative biopsies.<\/jats:p><jats:p>Methods: Eighty subjects were nonrandomly assigned to a three-arm trial to either bicalutamide 50 mg\/wk (n = 26) or 100 mg\/wk (n = 28) or no treatment (n = 26) for 6 months. Blood samples were obtained at 0, 3, and 6 months, and prostate biopsies were repeated after 6 months. The outcome measures were 6-month changes of tissue Ki-67 (primary end point), high-grade prostatic intraepithelial neoplasia (HG-PIN), proliferative inflammatory atrophy, circulating PSA, and sex hormones.<\/jats:p><jats:p>Results: Ki-67 expression was higher in HG-PIN than in normal tissue (10% versus 3%; P &amp;lt; 0.01) but was not modulated by bicalutamide in normal luminal cells. A trend toward an improvement of HG-PIN status was found in treated subjects (26% improved, 60% had no change, 15% worsened) as compared with the no-treatment arm (4% improved, 83% had no change, 13% worsened; P = 0.07). Proliferative inflammatory atrophy prevalence was not reduced by bicalutamide. Bicalutamide reduced PSA by 50% in both arms and raised testosterone and estradiol levels. Asymptomatic breast swelling was noted in 40% of the treated cases.<\/jats:p><jats:p>Conclusions: A weekly administration of bicalutamide seems to be reasonably safe and shows an encouraging signal of activity on HG-PIN prevalence, supporting further studies of this schedule in men at high risk despite the negative primary end-point findings on Ki-67.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-08-0205","type":"journal-article","created":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T02:06:23Z","timestamp":1238551583000},"page":"377-384","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase I-II Trial of Weekly Bicalutamide in Men with Elevated Prostate-Specific Antigen and Negative Prostate Biopsies"],"prefix":"10.1158","volume":"2","author":[{"given":"Silvia","family":"Zanardi","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Puntoni","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"},{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Maffezzini","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bandelloni","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Mori","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Argusti","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Campodonico","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Turbino","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Branchi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Decensi","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"},{"name":"Authors' Affiliations:\u20081Medical Oncology Unit, 2Urology Unit, 3Pathology Unit, and 4Clinical Chemistry and Microbiology Laboratory, Galliera Hospital; 5Biostatistics Unit, Department of Health Sciences, University of Genoa, Genoa, Italy; 6Section of Pathological Anatomy, Polytechnic University of the Marche Region, Ancona, Italy; and 7Division of Cancer Prevention and Genetics, European Institute of Oncology, Milan, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2009,4,6]]},"reference":[{"key":"2022060815491672600_bib1","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1158\/1078-0432.CCR-06-1104","article-title":"Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer\u2014a plan to move forward","volume":"12","author":"Kelloff","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060815491672600_bib2","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1200\/JCO.2005.08.027","article-title":"Prevention of hormone-related cancers: prostate cancer","volume":"23","author":"Parnes","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060815491672600_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/jnci\/dji009","article-title":"Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"97","author":"Lippman","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"2022060815491672600_bib4","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa030660","article-title":"The influence of finasteride on the development of prostate cancer","volume":"349","author":"Thompson","year":"2003","journal-title":"N Engl J Med"},{"key":"2022060815491672600_bib5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJMe038109","article-title":"The prevention of prostate cancer\u2014the dilemma continues","volume":"349","author":"Scardino","year":"2003","journal-title":"N Engl J Med"},{"key":"2022060815491672600_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1940-6207.CAPR-08-0085","article-title":"High-grade prostate cancer and the Prostate Cancer Prevention Trial","volume":"1","author":"Logothetis","year":"2008","journal-title":"Cancer Prev Res"},{"key":"2022060815491672600_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1158\/1940-6207.CAPR-08-0092","article-title":"Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach","volume":"1","author":"Redman","year":"2008","journal-title":"Cancer Prev Res"},{"key":"2022060815491672600_bib8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1464-410X.2005.06051.x","article-title":"Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer","volume":"97","author":"McLeod","year":"2006","journal-title":"BJU Int"},{"key":"2022060815491672600_bib9","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000463972","article-title":"The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing","volume":"18 Suppl 3","author":"Cockshott","year":"1990","journal-title":"Eur Urol"},{"key":"2022060815491672600_bib10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0090-4295(97)00029-0","article-title":"Comparison of in vitro effects of the pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen-sensitive parameters","volume":"49","author":"Simard","year":"1997","journal-title":"Urology"},{"key":"2022060815491672600_bib11","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/01.ju.0000087451.64657.fa","article-title":"A nomogram for predicting a positive repeat prostate biopsy in patients with a previous negative biopsy session","volume":"170","author":"Lopez-Corona","year":"2003","journal-title":"J Urol"},{"key":"2022060815491672600_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.0919-8172.2003.00605.x","article-title":"Predictors of prostate cancer on repeat prostatic biopsy in men with serum total prostate-specific antigen between 4.1 and 10 ng\/mL","volume":"10","author":"Okegawa","year":"2003","journal-title":"Int J Urol"},{"key":"2022060815491672600_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00001813-200309000-00003","article-title":"Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study","volume":"14","author":"Stratton","year":"2003","journal-title":"Anticancer Drugs"},{"key":"2022060815491672600_bib14","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/01.ju.0000139320.78673.2a","article-title":"Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial","volume":"172","author":"Andriole","year":"2004","journal-title":"J Urol"},{"key":"2022060815491672600_bib15","first-page":"314","article-title":"Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development","volume":"8","author":"O'Shaughnessy","year":"2002","journal-title":"Clin Cancer Res"},{"key":"2022060815491672600_bib16","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1056\/NEJMra021562","article-title":"Prostate cancer","volume":"349","author":"Nelson","year":"2003","journal-title":"N Engl J Med"},{"key":"2022060815491672600_bib17","unstructured":"National Cancer Institute-Common Terminology Criteria for Adverse Events, version 3.0, revised June 10, 2003. http:\/\/ctep.cancer.gov."},{"key":"2022060815491672600_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/jcp.53.9.655","article-title":"Morphological identification of the patterns of prostatic intraepithelial neoplasia and their importance","volume":"53","author":"Montironi","year":"2000","journal-title":"J Clin Pathol"},{"key":"2022060815491672600_bib19","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.pas.0000213289.50660.be","article-title":"A Working Group Classification of focal prostate atrophy lesions","volume":"30","author":"De Marzo","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"2022060815491672600_bib20","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jnci\/95.11.779","article-title":"A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers","volume":"95","author":"Decensi","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2022060815491672600_bib21","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rates: a practical and powerful approach to multiple testing","volume":"35","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc B"},{"key":"2022060815491672600_bib22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jcp.2006.040311","article-title":"Bicalutamide 50 mg monotherapy in patients with isolated high-grade PIN: findings in repeat biopsies at 6 months","volume":"60","author":"Bono","year":"2007","journal-title":"J Clin Pathol"},{"key":"2022060815491672600_bib23","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1464-410X.2006.06204.x","article-title":"Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg","volume":"98","author":"Scattoni","year":"2006","journal-title":"BJU Int"},{"key":"2022060815491672600_bib24","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0046-8177(98)90199-X","article-title":"Ki67 labeling index in core needle biopsies independently predicts tumor-specific survival in prostate cancer","volume":"29","author":"Bubendorf","year":"1998","journal-title":"Hum Pathol"},{"key":"2022060815491672600_bib25","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2004.09.150","article-title":"Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02","volume":"22","author":"Pollack","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022060815491672600_bib26","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/jnci\/91.21.1869","article-title":"Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence","volume":"91","author":"Agus","year":"1999","journal-title":"J Natl Cancer Inst"},{"key":"2022060815491672600_bib27","first-page":"933","article-title":"Suppression of advanced human prostate tumor growth in athymic mice by silibinin feeding is associated with reduced cell proliferation, increased apoptosis, and inhibition of angiogenesis","volume":"12","author":"Singh","year":"2003","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2022060815491672600_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-6-73","article-title":"Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer","volume":"6","author":"Ananthanarayanan","year":"2006","journal-title":"BMC Cancer"},{"key":"2022060815491672600_bib29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/modpathol.3800053","article-title":"High-grade prostatic intraepithelial neoplasia","volume":"17","author":"Bostwick","year":"2004","journal-title":"Mod Pathol"},{"key":"2022060815491672600_bib30","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2265.1994.tb02585.x","article-title":"Endocrine profiles during administration of the new nonsteroidal anti-androgen Casodex in prostate cancer","volume":"41","author":"Verhelst","year":"1994","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2022060815491672600_bib31","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2003.02.083","article-title":"Biology of prostate-specific antigen","volume":"21","author":"Balk","year":"2003","journal-title":"J Clin Oncol"},{"key":"2022060815491672600_bib32","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1200\/JCO.2006.07.6836","article-title":"Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial","volume":"25","author":"Thompson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2022060815491672600_bib33","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/ijc.23150","article-title":"Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia","volume":"122","author":"Zhigang","year":"2008","journal-title":"Int J Cancer"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/2\/4\/377\/2336131\/377.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/2\/4\/377\/2336131\/377.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T19:54:31Z","timestamp":1739044471000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/2\/4\/377\/47798\/Phase-I-II-Trial-of-Weekly-Bicalutamide-in-Men"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,1]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2009,4,6]]},"published-print":{"date-parts":[[2009,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-08-0205","relation":{},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"type":"print","value":"1940-6207"},{"type":"electronic","value":"1940-6215"}],"subject":[],"published":{"date-parts":[[2009,4,1]]}}}